Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD45RA+ Naive T Cell Depletion to Prevent GVHD in Older Patients With Acute Leukemia or MDS
NCT07819396Phase 2Not yet recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Jan 2027
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
A Phase 2 trial of CD45RA-depleted peripheral blood stem cells in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
CD45RA-depleted peripheral blood stem cells
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT07819396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07819396.